Heart Procedures: Life-Saving or Profit-Driven?

Modern medicine has made extraordinary strides in saving lives through surgical intervention. Procedures like coronary artery bypass grafting (CABG) and angioplasty have become mainstays of cardiac care, helping millions of patients manage heart disease. Yet beneath the impressive statistics and dramatic narratives of lives saved lies a troubling question: are these procedures always necessary, and do their benefits consistently outweigh their risks?

Understanding the Procedures

Coronary artery bypass grafting (CABG) involves redirecting blood flow around blocked coronary arteries using vessels harvested from other parts of the body. Angioplasty, often combined with stent placement, uses a balloon to widen narrowed arteries and a mesh tube to keep them open. Both procedures are primarily used to treat coronary artery disease (CAD), a condition in which plaques build up inside the arteries that supply the heart with blood.

These procedures have undoubtedly saved lives in acute settings, particularly in the context of heart attacks. The rapid restoration of blood flow to the heart during a myocardial infarction (heart attack) is critical to minimizing cardiac damage and improving survival rates.

The Evidence for Elective Procedures

However, the picture becomes significantly more complicated when it comes to elective procedures—those performed in stable patients without an acute emergency. A landmark study known as the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, published in the New England Journal of Medicine in 2007, found that in patients with stable coronary artery disease, adding angioplasty to optimal medical therapy did not reduce the risk of death, heart attack, or other major cardiovascular events compared to medical therapy alone.

This finding was replicated and extended by the ORBITA (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina) trial, which found that angioplasty did not significantly improve exercise time or decrease angina symptoms compared to a sham procedure. Yet despite these findings, elective angioplasties and stent placements continued to be performed by the hundreds of thousands annually in the United States.

The Profit Motive

Why would procedures continue to be widely performed despite evidence that they may not offer meaningful benefits to many patients? The answer, at least in part, lies in the enormous financial incentives driving interventional cardiology. A single coronary bypass surgery can cost $50,000 to $100,000, while angioplasty with stent placement typically runs $30,000 to $50,000.

Cardiologists and cardiac surgeons generate significant income from these procedures, and hospitals benefit from the substantial facility fees associated with them. Medical device manufacturers, including companies that produce stents, catheters, and surgical supplies, also have a vested interest in promoting procedural interventions over medical management.

The Role of Industry in Shaping Practice

The medical device and pharmaceutical industries spend billions of dollars annually marketing their products to physicians and healthcare systems. This marketing includes continuing medical education (CME) programs, speaker fees, consulting arrangements, and direct-to-consumer advertising, all of which can influence the clinical decisions of cardiologists.

Patient Perspectives and Informed Consent

For patients, the prospect of a "heart procedure" can be both terrifying and reassuring. The narrative of having a blockage cleared and the blood flow restored appeals to intuitive notions of fixing a broken system. Surgeons often present these procedures in terms of their potential benefits while downplaying the risks, including procedural complications, contrast-induced kidney injury, and the risks associated with anesthesia and hospitalization.

True informed consent requires that patients understand not only the potential benefits of a procedure but also the evidence that it may not offer advantages over less invasive treatments. Unfortunately, the current model of cardiac care often prioritizes intervention over a nuanced discussion of the alternatives.

A Call for Evidence-Based Practice

The field of cardiology has, to its credit, made some strides toward greater evidence-based practice in recent years. The ISCHEMIA (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) trial, published in 2020, further reinforced the findings of COURAGE, showing that invasive management did not significantly reduce the risk of major cardiovascular events in patients with stable ischemic heart disease compared to optimal medical therapy.

These findings underscore the need for a more critical evaluation of when cardiac procedures are truly warranted. Cardiology needs to move toward a model that prioritizes the best available evidence over financial incentives, that genuinely engages patients in shared decision-making, and that holds physicians accountable for adhering to evidence-based guidelines.

The stakes are high. When patients undergo unnecessary procedures, they are exposed to real risks—complications, prolonged recovery, and the psychological burden of being told their heart has a problem that requires surgical intervention. A healthcare system that truly puts patients first must have the courage to ask whether a procedure that generates enormous revenue is also generating commensurate health benefits.

Subscribe to Goldcare to access the full library of health insights ›